HEA 3050 Module 1 Women in Clinical Research Paper: From Exclusion to the 1993 Inclusion Law Example

Seventy Kilograms and Male: How Clinical Research Learned to Count Women

Student Name

B.S. in Health Studies, Thomas Edison State University

HEA-3050: Women's Health

Mentor Name

Month Day, Year

Seventy Kilograms and Male: How Clinical Research Learned to Count Women

Introduction

For most of the twentieth century, the typical subject of a drug trial was a man. Researchers assumed that what worked in men would work in women, and that women's hormonal cycles and the chance of pregnancy made them complicated and risky to study. This paper traces how that assumption was built into federal rules, how it was challenged and what changed after 1993. It argues that including women as participants was a necessary first step, but that the larger goal, learning whether treatments work differently in women and men, has been slower to reach.

How Exclusion Began

Two drug disasters shaped the rules. Thalidomide, prescribed for nausea in pregnancy in Europe in the late 1950s and early 1960s, caused severe limb defects in thousands of infants. Diethylstilbestrol, given to pregnant women in the United States for decades, was later linked to a rare vaginal cancer in their daughters. In response, the Food and Drug Administration issued guidance in 1977 recommending that women of childbearing potential be excluded from phase 1 and early phase 2 drug trials, the first studies of safety and dosing (Liu & DiPietro Mager, 2016). The guidance applied even to women using contraception, women whose partners had had vasectomies and single women who were not sexually active.

The intent was protective, but the effect reached far beyond pregnancy. Many large studies of the 1970s and 1980s, including a study of aspirin and heart attack in more than 22,000 physicians, enrolled only men, even though heart disease was and remains the leading cause of death in American women. Clinicians then applied the findings to women with little evidence that they held.

Pressure for Change

By the mid-1980s, women's health advocates, members of Congress and researchers argued that exclusion had become a danger of its own. A 1985 public health service task force concluded that the lack of research on women had compromised the quality of information about their health. The National Institutes of Health adopted a policy in 1986 urging inclusion of women, but a 1990 report by the General Accounting Office found the policy had been poorly communicated and seldom applied (Liu & DiPietro Mager, 2016). That report drew public attention and helped launch the Women's Health Initiative, the large federally funded study of postmenopausal women that began in 1991.

Policy Becomes Law

The NIH Revitalization Act of 1993 turned policy into law. It required research funded by the National Institutes of Health to include women and members of minority groups, and it required that phase 3 trials be built so that analysts could detect different effects in women or in minority groups. The same year, the Food and Drug Administration withdrew its 1977 restriction (Liu & DiPietro Mager, 2016).

Twenty Years Later

Mazure and Jones (2015) reviewed the state of research two decades after the law. Women's enrollment in NIH-funded clinical research had risen to about half of participants, a real change. But the authors found that many published trials still did not report results separately for women and men, so readers could not tell whether a treatment worked equally well for both. Enrolling women without analyzing results by sex, they argued, met the letter of the law without delivering its purpose.

The problem began earlier than human trials. Most laboratory studies used male animals and male cells, and few reported the sex of cells at all. Clayton and Collins (2014) announced that the National Institutes of Health would require applicants to describe how they would account for sex in laboratory work, using both male and female cells and animals, a policy that took effect in 2016. They wrote that relying on male animals had obscured sex differences that could guide clinical studies.

A Case of What Was Missed

Zolpidem, a widely prescribed sleeping pill, shows what is lost when sex differences go unexamined. Women clear the drug from their blood more slowly than men, so the same dose leaves more of it in a woman's body the next morning. In 2013, after reports of next-morning impairment, including while driving, the Food and Drug Administration cut the recommended dose of the immediate-release form for women in half, from 10 to 5 milligrams. The difference had been present in the data for years but had not shaped dosing until after the drug was in wide use.

Personal and Societal Influences

The HEA-3050 catalog entry points students toward the many layers, from personal and family to cultural, community and societal, that shape women's health. Research exclusion is a societal influence that reached individual women through their prescriptions. A woman taking a heart medicine or a sleeping pill did not know that its dose had been tested mostly in men. Her physician may not have known either. Women of color faced a double gap, since minority groups were also underrepresented, and analyses that combined sex and race were rarer still.

What Remains

Inclusion has improved, but gaps persist. Pregnant and breastfeeding women are still left out of most drug trials, so many medicines are used in pregnancy without trial data. Older women are underrepresented in trials of conditions that mostly affect older adults. Reporting by sex has improved but is not universal. Each of these gaps means that women and their clinicians still make decisions with less evidence than they need.

Conclusion

The exclusion of women from clinical research began as an effort to protect pregnancies and became a source of risk for all women. Advocacy, a federal audit and the 1993 law brought women into trials, and the 2014 policy extended attention to the laboratory. Yet as Mazure and Jones showed, counting women is not the same as learning from them. The zolpidem case shows the cost of that difference. Research that reports results by sex, and that includes pregnant and older women, remains the work ahead.

References

Clayton, J. A., & Collins, F. S. (2014). Policy: NIH to balance sex in cell and animal studies. Nature, 509(7500), 282-283. https://doi.org/10.1038/509282a

Liu, K. A., & DiPietro Mager, N. A. (2016). Women's involvement in clinical trials: Historical perspective and future implications. Pharmacy Practice, 14(1), Article 708. https://doi.org/10.18549/PharmPract.2016.01.708

Mazure, C. M., & Jones, D. P. (2015). Twenty years and still counting: Including women as participants and studying sex and gender in biomedical research. BMC Women's Health, 15, Article 94. https://doi.org/10.1186/s12905-015-0251-9